Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma Academic Article Article uri icon


MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Hypothyroidism
  • Indoles
  • Kidney Neoplasms
  • Pyrroles


  • Fifty-five patients with metastatic renal cell carcinoma (RCC) were treated on a multicenter, single-arm Phase II trial. Patients received single-agent Cetuximab (C225) administered by intravenous infusion at a loading dose of 400 or 500 mg/m2 followed by weekly maintenance doses at 250 mg/m2. None of the patients treated with C225 achieved either a complete or partial response. The median time to progression was 57 days. The most frequently reported grade 3 or 4 toxicity treatment-related adverse events were acne (17%) and rash or dry skin (4%). The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC.

publication date

  • February 2003



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1023/A:1022928612511

PubMed ID

  • 12795534

Additional Document Info

start page

  • 99

end page

  • 101


  • 21


  • 1